124186-29-4

Upstream product

• 111-25-1 1-bromo-hexane 
• 56552-80-8 (R)-3-benzyloxy-1,2-propanediol 

Downstream Products

• 854300-80-4 2-O-benzyl-1,3-bis-(1,2-di-O-hexyl-sn-glycero-3-phosphoryl)glycerol dimethyl ether 
• 854300-84-8 Phosphorous acid 2-benzyloxy-3-[((R)-2,3-bis-hexyloxy-propoxy)-methoxy-phosphanyloxy]-propyl ester (R)-2,3-bis-hexyloxy-propyl ester methyl ester 

Relevant academic research and scientific papers

Design and synthesis of lipid-coupled inositol 1,2,3,4,5,6-hexakisphosphate derivatives exhibiting high-affinity binding for the HIV-1 MA domain

The precursor of Gag protein (Pr55Gag) of human immunodeficiency virus, the principal structural component required for virus assembly, is known to bind d-myo-phosphatidylinositol 4,5-bisphosphate (PIP2). The N-terminus of Pr55G

Nonhydrolyzable analogs of phosphatidylinositol as ligands of phospholipases C

Phosphatidylinositol-specific phospholipases C (PI-PLCs) are important enzymes participating in transmembrane signal transduction. The structures of the two major species of these enzymes: bacterial Ca2+-nondependent enzyme from B. cereus and mammalian Ca2+-dependent PLCδ1 from rat brain in the complexes with the polar head groups of their substrates have been previously solved. Although these structures show few differences as compared to free enzymes, there is a compelling evidence that full catalytic activity of PI-PLC necessitates interaction of the enzyme with the entire substrate, including the hydrophobic fatty acid chains. In this work we develop new tightly binding and cleavage-resistant analogs of phosphatidylinositol, using relatively minor modifications of the structure. Two synthesized analogs, 2-amino-2-deoxy-PI (8) and the conformationally constrained analog (10) had binding affinities (K i) in 10 μM range. 15N-1H HSQC NMR spectra of uniformly 15N-labeled bacterial Ca2+-nondependent and Ca2+-dependent phospholipases C, btPLC and saPLC1, respectively, displayed changes upon ligand binding that suggest an occurrence of a conformational change.

NUCLEOSIDE-LIPID CONJUGATES, THEIR METHOD OF PREPARATION AND USES THEREOF

The invention provides methods for synthesizing nucleoside-lipid conjugates having varying fatty acid and alkyl chain lengths with or without unsaturation and their use in the treatment of cancer and viral diseases. More particularly, the invention provid

Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002)

A novel gemcitabine-lipid conjugate 5 was synthesized and tested for its in vivo efficacy and toxicity. Compound 5 was tested in BxPC-3 human pancreatic tumor model in SCID mice and exhibited promising activity and lower toxicity when compared with Gemzar

Inhibition of human erythrocyte membrane phosphatidylinositol 4-kinase by phospholipid analogues

Analogues of phosphatidylinositol (PtdIns, 1) have been synthesized to investigate the structural requirements for inhibition of a PtdIns 4-kinase obtained from human erythrocyte membranes. While the presence of either D-1 or D-3 stereochemistry in the inositol moiety greatly influences the degree of inhibition produced by PtdIns analogues, the stereochemistry of the glycerol moiety is of little consequence. Neither structural feature however, makes a significant contribution to binding affinity. Competitive inhibitory activity was found to be retained (or even enhanced) in substantially simpler analogues consisting of 1 or 2 hydrocarbon chains attached to a charged phosphate head group, such as in the phosphatidic acids, 24 and 26. The observation that the phosphatidylinositol 4-phosphate (PtdIns 4P) and phosphatidic acid analogues (eg, 16 or 17, and 26 respectively) inhibit PtdIns 4-kinase may suggest that such species have a regulatory role in PtdIns turnover.